Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.

MLA

Ryland, Georgina L., et al. “Inotuzumab Ozogamicin Resistance Associated with a Novel CD22 Truncating Mutation in a Case of B-Acute Lymphoblastic Leukaemia.” British Journal of Haematology, vol. 191, no. 1, Oct. 2020, pp. 123–26. EBSCOhost, https://doi.org/10.1111/bjh.16949.

APA

Ryland, G. L., Barraclough, A., Fong, C. Y., Fleming, S., Bajel, A., Hofmann, O., Westerman, D., Grimmond, S., & Blombery, P. (2020). Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. British Journal of Haematology, 191(1), 123–126. https://doi.org/10.1111/bjh.16949

Chicago

Ryland, Georgina L, Allison Barraclough, Chun Yew Fong, Shaun Fleming, Ashish Bajel, Oliver Hofmann, David Westerman, Sean Grimmond, and Piers Blombery. 2020. “Inotuzumab Ozogamicin Resistance Associated with a Novel CD22 Truncating Mutation in a Case of B-Acute Lymphoblastic Leukaemia.” British Journal of Haematology 191 (1): 123–26. doi:10.1111/bjh.16949.